Menopause's Genetic Grip on Heart Health Revealed

Heart disease remains the leading cause of death for American women. Recent research indicates that menopause's effect on the cardiovascular system may be more fundamental than previously understood, involving alterations to the body's gene regulation. A Virginia Tech review highlights that menopause appears to impact the epigenome, the system controlling gene activity, by reordering genetic expression within cardiovascular tissue. This finding, examining the role of epigenetics in heart disease, builds upon previous work showing shifts in estrogen-dependent signaling post-menopause.

Particular attention is given to heart failure with preserved ejection fraction (HFpEF), a condition more prevalent in women after menopause. Concurrently, a Penn State study reanalyzing Women's Health Initiative data from April 2025 suggests estrogen-based hormone therapy significantly improves cardiovascular markers. This therapy reduced LDL cholesterol by approximately 11% and favorably impacted HDL, total cholesterol, and insulin resistance.

Notably, hormone therapy lowered lipoprotein(a), a genetic risk factor for heart attack and stroke often unrecognized by women and unresponsive to diet or most medications. The timing hypothesis suggests HRT is most protective when initiated within 10 years of menopause or before age 60. While hormone therapy offers benefits, experts emphasize that diet, exercise, and metabolic health also play crucial roles in managing cardiovascular risk during midlife, a recognized turning point for women's heart health.